Considerations for Start-Up Biotech Company Valuation

Walter Bratic
OverMont Consulting
Justin R Blok
OverMont Consulting
Megan M Gostola
OverMont Consulting

DOI:https://doi.org/10.5912/jcb648

Abstract:

The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.

Keywords:valuation ,bio-tech ,start-up ,risk ,biologics ,en ,